Literature DB >> 22428655

6 months of "temporary" support by Levitronix left ventricular assist device.

Alessandro Barbone1, Pietro Giorgio Malvindi, Robert A Sorabella, Graziano Cortis, Paolo F Tosi, Alessio Basciu, Pietro Ferrara, Giuseppe Raffa, Enrico Citterio, Fabrizio Settepani, Diego Ornaghi, Giuseppe Tarelli, Ettore Vitali.   

Abstract

An otherwise healthy 47-year-old man presented to the emergency department in cardiogenic shock after suffering a massive myocardial infarction due to left main occlusion. He was initially supported by extracorporeal membrane oxygenation and subsequently was converted to paracorporeal support with a Levitronix left ventricular assist device. He experienced multiple postoperative complications including renal failure, respiratory failure, retroperitoneal hematoma requiring suspension of anticoagulation, and fungal bloodstream infection precluding transition to an implantable device. He was reconditioned and successfully underwent orthotopic heart transplant 183 days after presentation. A discussion of the relevant issues is included.
© 2012, Copyright the Authors. Artificial Organs © 2012, International Center for Artificial Organs and Transplantation and Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22428655     DOI: 10.1111/j.1525-1594.2011.01428.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  2 in total

1.  Optical aggregometry of red blood cells associated with the blood-clotting reaction in extracorporeal circulation support.

Authors:  Daisuke Sakota; Ryo Kosaka; Masahiro Nishida; Osamu Maruyama
Journal:  J Artif Organs       Date:  2016-03-24       Impact factor: 1.731

2.  Neurological complications after cardiac surgery: a retrospective case-control study of risk factors and outcome.

Authors:  Giuseppe Maria Raffa; Francesco Agnello; Giovanna Occhipinti; Roberto Miraglia; Vincenzina Lo Re; Gianluca Marrone; Fabio Tuzzolino; Antonio Arcadipane; Michele Pilato; Angelo Luca
Journal:  J Cardiothorac Surg       Date:  2019-01-25       Impact factor: 1.637

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.